• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Amgen to Acquire Five Prime Therapeutics for $1.9B

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Reed-Lane Facility Virtual Tour

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Reed-Lane

    Syngene

    Adare Pharma Solutions

    Cytovance Biologics
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    Reed-Lane

    Alcami

    Baxter BioPharma Solutions

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    FDA Watch

    Considerations for Analytical Method Validation Lifecycle Controls

    ICH is set to implement new regulatory guidance dedicated to analytical method development

    Considerations for Analytical Method Validation Lifecycle Controls
    Related CONTENT
    • Softweb Solutions
    • Syndax Pharma Gets IND Clearance for Leukemia Treatment
    • The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?
    • FDA Approves J&J's DARZALEX in Multiple Myeloma
    • Sierra’s Momelotinib Granted FDA Fast Track Designation
    Paul Mason, PhD, Lachman Consultants07.15.19
    The news that the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) intends to implement a new Quality Guideline, ICH Q14, “Analytical Procedure Development,” along with revising the ICH Q2(R1) Guideline on “Validation of Analytical Procedures: Text and Methodology,” is welcomed as, currently, there is no regulatory guidance dedicated to the topic of analytical method development.

    When providing documented evidence for the suitability of an analytical procedure, a company would commonly reach for the method validation report. However, as with a manufacturing process, the validation is just one component of the lifecycle for that process and a key element is the process development. With ICH Q14, it is expected that an analytical method development report will be an expected regulatory document that will accompany the validation report as part of the agency submission.

    A consideration at the initiation of the development phase for the analytical procedure is defining the goal/requirements for the test procedure. It is common for companies to validate a test procedure and report the results from the method validation in terms of accuracy, precision, and linearity, but rarely is there consideration as to whether the results of the method validation meet the requirements of the method’s intended use. Furthermore, a company’s analytical method validation standard operating procedure will commonly define the criteria for accuracy, linearity, precision, etc., with an assumption that such criteria are consistent for all quantitative test procedures.

    Currently, there is no regulatory guidance on establishing the criteria. The upcoming ICH Q14 guideline may recommend that the analytical method validation criteria consider the material specification range for the attribute the test procedure is to measure—a similar approach when defining an analytical test method system suitability requirement. For quantitative test procedures, it should be recognized that the reported result only approximates the actual value for the material attribute that is being measured, and that there is an “uncertainty” associated with the reported result.

    The USP analytical product lifecycle stimuli article by Martin, G.P., et al., “Lifecycle Management of Analytical Procedures: Method Development, Procedure Performance Qualification, and Procedure Performance Verification,” Pharmacopeial Forum 39(5), September–October 2013, refers to an “Analytical Target Profile” (ATP) where it is defined as the required quality of the reportable value from a test procedure in terms of Target Measurement Uncertainty (TMU) In turn, TMU is the maximum measurement of uncertainty that the reportable result can have where the method can still be considered fit for use. Both the test procedure’s precision and bias contribute to the TMU. The acceptability of the TMU considers the specification range for the attribute that is being reported and assesses the risk of an investigation being required due to the uncertainty of the value that is generated by the test procedure. 

    The Eurachem/CITAC 2015 guide “Setting and Using Target Uncertainty in Chemical Measurement” references that the Target Uncertainty (Utg) should be eight times smaller than the compliance range Utg = Qmax – Qmin/8. Essentially, any method where the measurement uncertainty consumes the material specification range is not a suitable method. It should also be understood that the various sources of the method uncertainty are cumulative. For example, Little, T., “Establishing Acceptance Criteria for Analytical Methods,” Biopharm International 29 (10) 2016, recommended that the repeatability is evaluated as follows: Repeatability % Tolerance = (StDev Repeatability * 5.15)/(USL – LSL) where the criteria is less than 25% and that for bias the criteria is as follows: Bias % of tolerance = bias/(USL – LSL) * 100 where the criteria is less than 10%. [Note: USL = Upper Specification Limit and LSL = Lower Specification Limit.]

    As the effects of bias and repeatability are cumulative and the reduction of one would allow a larger value for the other, there is a benefit of assessing the impact of bias and repeatability in combination. USP Chapter <1210>, Statistical Tools for Procedure Validation, provides guidance as such where tolerance intervals can be calculated from a series of experiments utilizing a Control Sample (CS). A CS is invaluable in demonstrating the continued suitability of the method when used as part of the method lifecycle control. The CS will be extensively characterized, commonly by duplicate analysts, by the subject test procedure, but also by an orthogonal procedure and there will also be a theoretical understanding for the level of the analyte from the synthesis. The goal from the characterization is to define an accurate level of analyte within the CS, and thus, provide an accurate bias value for the method. The testing of the CS will be defined within the test procedure and will be part of the method’s system suitability.

    Tolerance intervals for the CS can be calculated as follows: Xbar ± KS

    Where S is the standard deviation for the multiple measurements of the CS, Xbar is the afforded mean, and K is the percentage of the population at a certain level of confidence. For example, the value of K required to enclose 95% of the population with 95% confidence for fifty samples is 2.382. The repeated measurements of the CS will provide an assessment of the method’s bias and repeatability. 

    As part of the initial method validation, and through periodic assessment of method performance, the demonstrated method capability tolerance intervals should be compared to a criterion. This method validation criterion would be based upon the defined analyte concentration of the CS and an acceptable interval, based upon the TMU. Such an approach aligns with the USP stimuli article by Martin, G.P., et al., “Proposed New USP General Chapter – The Analytical Procedure Lifecycle <1220>,” Pharmacopeial Forum 43 (1), January 2017, where there is reference to Example 2 for the ATP, which states that the reportable value for the analyte must be within a TMU of ± C% where the TMU is a fraction of the specification range and considers the acceptable difference between a measured value and target value.

    Through method development, there should be an understanding what analytical method attributes impact the analytical target profile. The FDA’s July 2015 Guidance for Industry: “Analytical Procedures and Method Validation for Drugs and Biologics,” recommended that method development includes an assessment of method robustness through design of experiments systematic testing where it is understood which method attributes will impact the instrument output, the reported result, and, thus, the measurement uncertainty.

    Ultimately, through a robust method development, there would be fewer investigations, such as OOS, where the root cause is the method measurement uncertainty not aligning with the material specification range, rather than the quality of the material that is being tested. It is recommended that robustness is evaluated during the method development phase, when the necessary method controls are defined and confirmed for suitability via method validation.

    A question that may be raised by industry professionals is, “How does the upcoming ICH Q14 guideline impact the methods that I currently use?” The FDA’s July 2015 Guidance for Industry: “Analytical Procedures and Method Validation for Drugs and Biologics” references analytical method development, the use of statistical tools during method validation, and lifecycle management of analytical procedures. It is recommended that for in-use methods there is a program for periodic assessment of the method performance/capability where continued method suitability is confirmed. This can be assessed via an evaluation of investigations, which involves data that is generated by the method, and determining through trend analysis whether method capability was a potential cause. 

    There should also be a continual assessment of the method system suitability test regime and criteria when there is verification that the method’s system suitability is sufficiently discriminative and meets the method’s needs. Further, there should be consideration of incorporating a CS to ensure that the measured method’s uncertainty continues to align with the TMU. The periodic method assessment should also verify that there is an understanding, through method robustness studies, of the critical method attributes and their impact on the method’s measured uncertainty value.

    One of the significant benefits of a comprehensive and structured analytical method development program is understanding the potential impact of any “change” to the method. For lifecycle management of the test procedure, it is recommended that risk assessment, per ICH Q9, “Quality Risk Management,” is utilized to determine the potential impact of any change—be it to the method itself or the manufacturing process it is supporting—to the method uncertainty value and then assessing the need for method redevelopment or revalidation.

    Historically, analytical method validation was the exercise to demonstrate that a method was “fit for purpose.” The goal is to determine what the requirements for the method are in terms of the material/process that is being tested, define the ATP (which for quantitative methods considers the TMU), and then, through a structured method development program, demonstrate that the developed method meets the requirements of the ATP—and that it is known which method critical attributes impact the ability to meet the ATP. Therefore, the method development report is critical when evaluating the potential impact of any proposed change to the method.

    It is recognized that ICH Q2(R1) does not provide specific guidance for the development and validation of non-chromatographic methods. However, the FDA’s March 2015 Draft Guidance for Industry: “Development and Submission of Near Infrared Analytical Procedures” provides direction for the development and validation of a spectroscopic PAT analytical method. This document also provides expectations on what should be submitted within the regulatory filing relating to the development of the PAT method along with the method validation. In addition, there is also guidance relating to the lifecycle management of such a method and considerations for when further method development/revalidation is required. It is recognized that this guidance is geared towards the development and validation of a NIR PAT method, and, as such, a significant focus of the guidance is towards the development and validation of the calibration model using chemometric software to define the relationship between NIR spectral output to the analyte of interest. However, it is expected that the upcoming ICH Q14 guideline and revised ICH Q2(R1) guideline will have similar focus on method development for both chromatographic and non-chromatographic methods.


    Paul Mason, PhD
    Lachman Consultants

    Paul Mason is a director in the science and technology practice at Lachman Consultants. With over 17 years of experience in the pharmaceutical industry, he is a quality control chemist experienced in sterile parenteral, API, and solid oral dosage forms. His experience spans finished dosage form, CMOs, and API intermediates manufacture support in both a quality control and analytical development setting. For further information please contact the author at p.mason@lachmanconsultants.com.
    Related Searches
    • Manufacturing
    • pat
    • biologics
    • software
    Suggested For You
    Softweb Solutions Softweb Solutions
    Syndax Pharma Gets IND Clearance for Leukemia Treatment Syndax Pharma Gets IND Clearance for Leukemia Treatment
    The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up? The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?
    FDA Approves J&J FDA Approves J&J's DARZALEX in Multiple Myeloma
    Sierra’s Momelotinib Granted FDA Fast Track Designation Sierra’s Momelotinib Granted FDA Fast Track Designation
    Risk-Based Monitoring Risk-Based Monitoring
    Aclaris Therapeutics Submits IND for RA Treatment Aclaris Therapeutics Submits IND for RA Treatment
    The Orphan Promise The Orphan Promise
    Effective Post Market Supplier Strategy for Combination Products Effective Post Market Supplier Strategy for Combination Products
    Nitrosamines Nitrosamines
    BioSpectra Launches Bulk Mfg. Process BioSpectra Launches Bulk Mfg. Process
    Lachman Consultants Names Compliance Services VP Lachman Consultants Names Compliance Services VP
    KASA to Support Generic Drug Review KASA to Support Generic Drug Review
    FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an
    Are We Embracing FDA’s Messages? Are We Embracing FDA’s Messages?

    Related FDA Watch

    • Solid Dosage/Creams/Ointments
      Recent Advances in Solid Dispersion Technologies

      Recent Advances in Solid Dispersion Technologies

      Improving the bioavailability and therapeutic efficiency of poorly soluble drugs.
      José L. Toro, Directory, Lachman Consultants 01.27.21

    • The Importance of Hypothesis Testing During Investigations

      The Importance of Hypothesis Testing During Investigations

      Why it is critical to have controls in place during out-of-specification investigations to provide quality assurance.
      Paul Mason, PhD, Lachman Consultants 11.17.20

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      Ensuring Manufacturing Continuity for Essential Medicines

      Ensuring Manufacturing Continuity for Essential Medicines

      Applying the principles of Quality Risk Management to get medicines to market faster.
      John Darby, M.Sc., Senior Director, Lachman Consultant Services, Inc. 09.09.20


    • Biologics, Proteins, Vaccines
      Pharma’s Fight Against the Coronavirus Pandemic

      Pharma’s Fight Against the Coronavirus Pandemic

      A look at the pharma industry’s concerted effort to develop vaccines against the SARS-CoV-2 virus and therapeutics to treat COVID-19.
      Keith O. Webber, Lachman Consultant Services, Inc. 07.15.20

    • Information Technology | Regulatory Affairs
      Data Integrity: Beyond Electronic Records

      Data Integrity: Beyond Electronic Records

      Get your Data Integrity house in order
      Tim Rhines, Ph.D., Director, Lachman Consultant Services, Inc. 05.05.20

    • Regulatory Affairs
      Inquiring Minds Want to Know, Just Ask FDA

      Inquiring Minds Want to Know, Just Ask FDA

      What you need to know prior to submission
      Michelle Ryder, Lachman Consultant 04.01.20


    • Regulatory Affairs
      The Art of Filing NDA/ANDA Post-Approval Changes to the FDA

      The Art of Filing NDA/ANDA Post-Approval Changes to the FDA

      Some tips to make your trip along the regulatory pathway to report manufacturing changes easier.
      Amy Schutte, Senior Associate, Lachman Consultant Services 03.04.20

    • Regulatory Affairs
      Inactive Ingredients: Where Guidance Needs to Meet Data

      Inactive Ingredients: Where Guidance Needs to Meet Data

      Looking at FDA’s most recent draft guidance and the struggle with inactive ingredients.
      Sharif Ahmed, Lachman Consultants Services 10.15.19

    • Regulatory Affairs
      Continuous Manufacturing and its Regulatory Challenge

      Continuous Manufacturing and its Regulatory Challenge

      ...
      José L. Toro, PhD, Lachman Consultants 09.16.19


    • Regulatory Affairs
      Effective Post Market Supplier Strategy for Combination Products

      Effective Post Market Supplier Strategy for Combination Products

      Combinations are typically designed, developed and maintained under a robust contract manufacturing process
      Lori-Ann Woodard CBA, CQE, CSQE, Lachman Consultant Services 06.13.19

    • QA/QC
      Nitrosamines

      Nitrosamines

      How to address these unwelcome guests in the pharmaceutical world
      Aloka Srinivasan, Ph.D., Lachman Consultant Services 05.07.19

    • Regulatory Affairs
      KASA to Support Generic Drug Review

      KASA to Support Generic Drug Review

      FDA expects the new system to advance OPQ’s focus on pharmaceutical quality, the foundation for ensuring the safety and efficacy of drugs.
      Sharif Ahmed, Lachman Consultant Services 04.05.19


    • Regulatory Affairs
      FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an

      FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an

      A look at how the FDA will administer the transition of NDAs to BLAs
      Keith Webber, Ph.D., Lachman Consultant Services 03.06.19

    • Regulatory Affairs
      Reporting CPPs to FDA

      Reporting CPPs to FDA

      Importance of identifying critical process parameters in original submissions to FDA.
      Aloka Srinivasan, Ph.D. Lachman, Consultant Services 10.10.18

    • Regulatory Affairs
      FDA and Field Alert Reports

      FDA and Field Alert Reports

      Analysis of “Field Alert Report Submission Questions and Answers Guidance for Industry”
      Constance Richard-Math, Lachman Consultants 09.11.18

    Trending
    • Catalent Acquires Delphi Genetics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • WuXi AppTec Completes OXGENE Acquisition
    Breaking News
    • Amgen to Acquire Five Prime Therapeutics for $1.9B
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    • CureVac, Novartis Ink COVID Vax Mfg. Pact
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Statins May Contribute to Vascular Calcification by Inhibiting Vitamin K-Dependent Proteins
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Maroon Group Acquires Cary Company's Raw Materials, Specialty Chemicals Distribution Business
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    EchoNous Expands Its Kosmos Hardware Platform
    Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib
    Europe's Cross-Border Medtech Deal Activity Rises in Q4 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Amgen to Acquire Five Prime Therapeutics for $1.9B
    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    CureVac, Novartis Ink COVID Vax Mfg. Pact
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Establishes Equity and Engagement Center of Excellence
    L'Oreal On How It Will Shape Beauty's Future at Today's Transparency Summit
    C.O. Bigelow Earns Praise as NYC's Oldest Family-Run Apothecary
    Happi

    Latest Breaking News From Happi

    Avon Launches Vegan Skin Care Line
    Inolex Appoints VP Marketing
    Decorté Launches AI Diagnostics in US
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Springfield Solutions highlights digital label embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints Managing Director, China and Asia Pacific
    Full-Year Sales Down 12 Percent at Zimmer Biomet
    Lincotek Medical Expands Coatings and Additive Capacity
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login